chemotherapy regimen, cumulative dose, and patient age. Most ovarian toxicity is due to alkylating agents, with moderate effects from doxorubicin or cisplatin and fewer effects from fluorouracil, methotrexate, vincristine, paclitaxel, and docetaxel. This
Search Results
Life After Treatment: Quality-of-Life Concerns in Patients Treated for Cancer
Mindy E. Goldman
Vulvar Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology
Wui-Jin Koh, Benjamin E. Greer, Nadeem R. Abu-Rustum, Susana M. Campos, Kathleen R. Cho, Hye Sook Chon, Christina Chu, David Cohn, Marta Ann Crispens, Don S. Dizon, Oliver Dorigo, Patricia J. Eifel, Christine M. Fisher, Peter Frederick, David K. Gaffney, Ernest Han, Susan Higgins, Warner K. Huh, John R. Lurain III, Andrea Mariani, David Mutch, Christa Nagel, Larissa Nekhlyudov, Amanda Nickles Fader, Steven W. Remmenga, R. Kevin Reynolds, Todd Tillmanns, Stefanie Ueda, Fidel A. Valea, Emily Wyse, Catheryn M. Yashar, Nicole McMillian, and Jillian Scavone
alternative in this setting. Agents recommended by the panel for treating advanced recurrent/metastatic disease include cisplatin, carboplatin, paclitaxel (category 2B), and erlotinib (category 2B) as single agents and cisplatin/vinorelbine, cisplatin/paclitaxel
New Developments in Thyroid Cancer
Robert I. Haddad
. Dr. Haddad noted, “we routinely use concurrent chemoradiotherapy in patients who undergo a complete surgical resection and our preferred regimen is weekly carboplatin and paclitaxel. Refer these patients immediately for a clinical trial if one is
Management of EGFR Mutation–Positive Non–Small Cell Lung Cancer
Rogerio A. Lilenbaum and Leora A. Horn
/or honoraria from Genentech, Inc. and Merck & Co., Inc. References 1. Mok TS Wu YL Thongprasert S . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma . N Engl J Med 2009 ; 361 : 947 – 957 . 2. Yang JC Wu YL Schuler M
Does Chemoradiation Benefit Patients With Gastric Cancer Managed Without Surgery?
Kimberly L. Johung and Stacey M. Stein
, with concurrent fluorouracil and paclitaxel. A pathologic CR was achieved in 26% of patients, with improved survival in these patients. 11 The ongoing phase III TOPGEAR trial is evaluating the addition of preoperative CRT to perioperative chemotherapy
Multimodality Approaches to Localized Gastric Cancer
Prajnan Das, Yixing Jiang, Jeffrey H. Lee, Manoop S. Bhutani, William A. Ross, Paul F. Mansfield, and Jaffer A. Ajani
2 cycles of 5-FU, paclitaxel, and cisplatin, followed by radiotherapy with concurrent paclitaxel and infusional 5-FU, with 40 patients then undergoing surgery. 47 This study showed a pathologic complete response rate of 20%, R0 resection rate of 78
Controversies in the Surgical Management of Gastric Cancer
David A. Kooby and Daniel G. Coit
, randomised trial of adjuvant chemotherapy or radiotherapy in resectable gastric cancer: Interim report . Br J Cancer 1989 ; 60 : 739 – 744 . 55 Kelsen DP Schwartz G Janjan N Minsky B . A randomized phase II comparison of two cisplatin-paclitaxel
Principles and Techniques of Radiation Therapy for Esophageal and Gastroesophageal Junction Cancers
Lisa Hazard, Gary Yang, Mary Frances McAleer, James Hayman, and Christopher Willett
: a randomized phase II study of two paclitaxel-based chemoradiotherapy regimens . Available at : http://www.rtog.org/members/protocols/E0113/E0113.pdf . Accessed 3 September 2008 . 13. Tachibana M Kinugasa S Yoshimura H . Clinical
Crescendos and Decrescendos: Gastric and Esophageal Cancers
Jaffer A. Ajani
Dutch trial 15 that randomly assigned 363 patients to receive either chemoradiation (paclitaxel plus carboplatin with 40 Gy of radiation) and surgery (n = 175) or surgery alone (n = 188), patients who received preoperative chemoradiation had
The Abu Dhabi Declaration: Why the Hustle?
Hamdy A. Azim, Abdul-Rahman Jazieh, and Mohammad Jahanzeb
of non-small-cell lung cancer to gefitinib . N Engl J Med 2004 ; 350 : 2129 – 2139 . 4. Mok TS Wu YL Thongprasert S . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma . N Engl J Med 2009 ; 361 : 947 – 957 . 5
